Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Feasibility Trial for Primary Stroke Prevention in Children with Sickle Cell Anemia in Nigeria (SPIN Trial)

Najibah Aliyu Galadanci, MBBS MPH, Shehu Umar Abdullahi, MBBS, Leah Danielle Vance, BS, Musa Tabari, MBBS, Shehi Abubakar, MBBS, Belonwu Raymond, MBBS, Salihu Auwal, MBBS, Aisha Amal Galadanci, MBBS, Binta WUDIL Jibir, MBBS MPH, Halima Bello-Manga, MBBS, MPH, Kathleen A Neville, MD MS, Fenella Kirkham, MD, Yu Shyr, MD, Sharon E. Phillips, MSPH, Brittany Covert, MPH, CCRP, Adetola A. Kassim, MD MS, Lori Jordan, MD, Muktar Aliyu, MD PhD, Michael DeBaun, MD

Blood (2016) 128 (22): 122.

https://doi.org/10.1182/blood.V128.22.122.122

Published: 2016

Journal Articles

Pharmacokinetics in Children with Sickle Cell Anemia Following Single Dose Versus Chronic Treatment with Hydroxyurea

Joana Marie Mack, MD, Pawel Wiczling, PhD, Joseph Moen, MS, Guolian Kang, PhD, Robert I. Liem, MD MS, Julie A. Panepinto, MD MSPH, Gregory Kearns, PharmD, PhD FCP, FAAP, Kathleen A Neville, MD MS, Jeremie H. Estepp, MD

Blood (2016) 128 (22): 1314.

https://doi.org/10.1182/blood.V128.22.1314.1314

Published: 2016

Journal Articles

Acceptability and Safety of Hydroxyurea for Primary Prevention of Stroke in Children with Sickle Cell Disease in Nigeria

Michael R. DeBaun, MD MPH, Najibah Aliyu Galadanci, MBBS, Shehu U. Abdullahi, MD FWACPaed, Musa A. Tabari, MBBS, FMCR, FICS, Shehi Abubakar, MBBS, Raymond Belonwu, MBBS, FWACPaed, Auwal Salihu, MBBS, FMCPsych, Kathleen A Neville, MD MS, Fenella J. Kirkham, MD, Baba PD Inusa, MD FRCPCH, DCP, Yu Shyr, PhD, Sharon Phillips, MSPH, Adetola A. Kassim, MD, Lori C. Jordan, MD, Muktar H. Aliyu, MD DrPH, MPH, Brittany V. Covert, MPH

Blood (2014) 124 (21): 4021.

https://doi.org/10.1182/blood.V124.21.4021.4021

Published: 2014

Journal Articles

Relative Oral Bioequivalence of Two 6-Mercaptopurine (6-MP) Liquid Formulations in Children with Acute Lymphoblastic Leukemia (ALL)

Jaszianne A. Tolbert, MD, Keith J. August, MD MS, Susan M Abdel-Rahman, PharmD, Scott J Weir, PharmD, PhD, J Steven Leeder, PharmD, PhD, Kathleen A Neville, MD MS

Blood (2014) 124 (21): 2242.

https://doi.org/10.1182/blood.V124.21.2242.2242

Published: 2014

Journal Articles

Health-Related Quality of Life in Children with Sickle Cell Disease: Impact of Blood Transfusion Therapy

Lauren M Beverung, MS, PhD, John J. Strouse, MD PhD, Monica L. Hulbert, MD, Kathleen A Neville, MD MS, Robert I. Liem, MD, Baba PD Inusa, MD FRCPCH, DCP, Beng Fuh, MD, Allison King, MD MPH, Emily R. Meier, MD, James F. Casella, MD, Michael R. DeBaun, MD MPH, Julie A. Panepinto, MD MSPH

Blood (2014) 124 (21): 2167.

https://doi.org/10.1182/blood.V124.21.2167.2167

Published: 2014

Journal Articles

Phase 1/2 Study Of Brentuximab Vedotin In Pediatric Patients With Relapsed Or Refractory (R/R) Hodgkin Lymphoma (HL) Or Systemic Anaplastic Large-Cell Lymphoma (sALCL): Preliminary Phase 2 Data For Brentuximab Vedotin 1.8 Mg/Kg In The HL Study Arm

Franco Locatelli, MD, Kathleen A Neville, MD, MS, Angelo Rosolen, MD, Judith Landman-Parker, MD, Nathalie Aladjidi, MD, Auke Beishuizen, MD, Stephen Daw, BSc Hons, MBChB, MRCP, Lia Gore, MD, Anna R.K. Franklin, MD, Adedigbo Fasanmade, PhD, Jingyuan Wang, PhD, Jessica Sachs, MD, Christine Mauz-Koerholz, MD

Blood (2013) 122 (21): 4378.

https://doi.org/10.1182/blood.V122.21.4378.4378

Published: 2013

Journal Articles

Population Pharmacokinetic (PK) Modeling of Hydroxyurea for Therapeutic Drug Monitoring Applications in Children and Adolescents with Sickle Cell Disease

Pawel Wiczling, PhD, Robert I. Liem, MD, Julie A. Panepinto, MD, MSPH, Uttam Garg, PhD, Susan M. Abdel-Rahman, PharmD, Gregory L Kearns, PharmD, PhD, Kathleen A Neville, MD, MS

Blood (2011) 118 (21): 2136.

https://doi.org/10.1182/blood.V118.21.2136.2136

Published: 2011

NARROW

Feasibility Trial for Primary Stroke Prevention in Children with Sickle Cell Anemia in Nigeria (SPIN Trial)

Pharmacokinetics in Children with Sickle Cell Anemia Following Single Dose Versus Chronic Treatment with Hydroxyurea

Acceptability and Safety of Hydroxyurea for Primary Prevention of Stroke in Children with Sickle Cell Disease in Nigeria

Relative Oral Bioequivalence of Two 6-Mercaptopurine (6-MP) Liquid Formulations in Children with Acute Lymphoblastic Leukemia (ALL)

Health-Related Quality of Life in Children with Sickle Cell Disease: Impact of Blood Transfusion Therapy

Phase 1/2 Study Of Brentuximab Vedotin In Pediatric Patients With Relapsed Or Refractory (R/R) Hodgkin Lymphoma (HL) Or Systemic Anaplastic Large-Cell Lymphoma (sALCL): Preliminary Phase 2 Data For Brentuximab Vedotin 1.8 Mg/Kg In The HL Study Arm

Population Pharmacokinetic (PK) Modeling of Hydroxyurea for Therapeutic Drug Monitoring Applications in Children and Adolescents with Sickle Cell Disease

Email alerts

ASH Publications

American Society of Hematology

Feasibility Trial for Primary Stroke Prevention in Children with Sickle Cell Anemia in Nigeria (SPIN Trial)

Pharmacokinetics in Children with Sickle Cell Anemia Following Single Dose Versus Chronic Treatment with Hydroxyurea

Acceptability and Safety of Hydroxyurea for Primary Prevention of Stroke in Children with Sickle Cell Disease in Nigeria

Relative Oral Bioequivalence of Two 6-Mercaptopurine (6-MP) Liquid Formulations in Children with Acute Lymphoblastic Leukemia (ALL)

Health-Related Quality of Life in Children with Sickle Cell Disease: Impact of Blood Transfusion Therapy

Phase 1/2 Study Of Brentuximab Vedotin In Pediatric Patients With Relapsed Or Refractory (R/R) Hodgkin Lymphoma (HL) Or Systemic Anaplastic Large-Cell Lymphoma (sALCL): Preliminary Phase 2 Data For Brentuximab Vedotin 1.8 Mg/Kg In The HL Study Arm

Population Pharmacokinetic (PK) Modeling of Hydroxyurea for Therapeutic Drug Monitoring Applications in Children and Adolescents with Sickle Cell Disease

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only